Sanofi unifies under a new logo and a new structure
Sanofi has been a global healthcare leader that has developed treatments for rare diseases and established gold standard treatments for areas such as diabetes and cardiovascular disease. After 50 years, the France-based company is giving itself a bit of a brand makeover with a new logo and a restructuring of its corporate umbrella in support of its three-year-old “Play to Win” strategy.
Sanofi Chief Executive Paul Hudson called it “the most significant transformation and modernization” in the company’s five-decade history.
“In 2019, we launched our Play to Win strategy, which focuses on applying our innovation platform to produce world-class treatments and vaccines. Our new brand is a natural and important next step in this journey and represents the integrated way the company will work to achieve our shared ambition to transform the practice of medicine,” Hudson said in a statement.
From now on, the entire company will be united under the same Sanofi banner. The current Sanofi Pasteur and Sanofi Genzyme business units, which focus on vaccines and specialty care respectively, along with all other acquired brands, will be united under the singular Sanofi name and brand.
Having all entities operating under the same umbrella and with a common purpose will position the company “to achieve greater impact by more strategically applying the resources that exist across the business to drive the innovations that matter,” said Sanofi said in its announcement.
The new company logo includes a colon at the beginning and end of the word Sanofi. Sanofi said the dots represent the beginning and end of the scientific journey.
“The two purple dots embody the scientific journey between a starting point – the curiosity to question the status quo and ask ‘what if?’ — and a finish line — the eureka moment where innovative solutions are unlocked to impact people’s lives,” the company said.
Sanofi continued with its new logo and new structure with a positive year-end sales report which saw significant profits driven by Dupixent, the blockbuster active for asthma and eczema co-developed with Regeneron.
Over the past year, Dupixent has been approved in the United States for the treatment of moderate to severe asthma in children 6-11 years of age and has also been shown effective in multiple type 2 inflammatory indicationsincluding prurigo nodularis and eosinophilic esophagitis.
In addition to Dupixent, the company’s vaccines business was also an important driver. Dupixent saw its sales increase by 53% in 2021. The drug brought in around $6 billion for the year. The company’s flu vaccines also saw record sales in 2021.
“In R&D, we continue to be relentless in our commitment to expanding our portfolio of innovations. Last quarter, Sanofi achieved a new milestone, a first in recent years, by advancing seven molecules into Phase I and seven pipeline programs into Phase II trials, demonstrating our success in rapidly advancing potentially transformative drugs,” said Hudson said in a statement.